“This collaboration between Lonza and IsoPlexis highlights the evolution of cell therapy manufacturing,” notes Matthew Hewitt, PhD, Head of Clinical Development and Personalized Medicine at Lonza. “As we continue to scale the manufacturing of cell therapies, it will be critical to characterize the quality and performance of these products with technologies such as IsoPlexis’ IsoLight.”
Other participants in the study include health workers within Providence St. Joseph Health and the Swedish Medical System, as well as collaborators from Stanford University, IsoPlexis, Adaptive Biotechnologies, 10x Genomics, Metabolon and others.
Merck will provide research funding and work with ISB researchers to find targets for potential interventions, including drugs, antibody therapies and vaccines. The study will initially analyze samples from 200 patients with the potential to expand to 300.